Inalimarev

{
  "id": "MLC-T-ONC-004257",
  "term": "Inalimarev",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A cancer vaccine made with a form of vaccinia virus that does not cause disease in humans. It is being studied in the treatment of some types of cancer. The virus is changed in the laboratory to make human proteins, including the tumor markers called CEA and MUC-1, that may help immune cells in the body kill tumor cells. Also called PANVAC-V and recombinant vaccinia-CEA-MUC-1-TRICOM vaccine.",
    "A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells."
  ],
  "abbreviation": "vCEA-MUC-1-TRI",
  "synonyms": [
    "PANVAC-V",
    "recombinant vaccinia-CEA-MUC-1-TRICOM vaccine",
    "recombinant vaccinia-CEA(D609)/MUC1(L93)/TRICOM vaccine",
    "vaccinia-CEA-MUC-1-TRICOM vaccine",
    "rVaccinia-CEA(D609)/MUC1(L93)/TRICOM vaccine",
    "recombinant vaccinia-CEA-MUC1-TRICOM vaccine"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/inalimarev/"
}